NCT06427226 2026-04-17
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Tanta University
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05521984 2026-04-02
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
Phase 1 Recruiting
NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
NCT07436663 2026-02-27
SGLT2i/DPPi
Tanta University
Phase 4 Not yet recruiting
NCT07235280 2026-02-19
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT07310433 2025-12-30
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
The University of Hong Kong
Phase 2 Not yet recruiting
NCT07245069 2025-11-24
Alpaca
University Medical Centre Ljubljana
Phase 2 Recruiting
NCT04887935 2025-10-01
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT06491680 2025-09-22
Cardiotoxicity in Breast Cancer Patients
Helwan University
Phase 4 Recruiting
NCT06888505 2025-09-18
DAPA-AIC
Hawler Medical University
Phase 2 Completed
NCT07070765 2025-07-23
SPRINT
University of Aberdeen
Phase NA Not yet recruiting
NCT07033585 2025-07-11
GD-T2D
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting